Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C.
A high molecular weight derivative of mitomycin C (MMC), mitomycin C-dextran conjugate (MMC-D) has been synthesized and its biological and pharmacological properties investigated. MMC is released from MMC-D in vitro with a half-life of 24 h. After intraperitoneal injection of MMC-D, free MMC could be detected in plasma and urine of mouse for 5--8 h, while MMC administered as a free form was eliminated rapidly. After MMC-D, given to mice bearing Ehrlich ascites carcinoma or B16 melanoma there was a reduction in toxicitst that the high molecular weight MMC-dextran derivative is a kind of pro-drug which persists in the body giving a sustained release of free MMC thus significantly increasing the antitumour activity of the parent drug.
D000818:Animals; D000970:Antineoplastic Agents; D002478:Cells, Cultured; D003692:Delayed-Action Preparations; D003911:Dextrans; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008937:Mitomycins / Q000378:metabolism / Q000494:pharmacology; D008970:Molecular Weight; D009374:Neoplasms, Experimental / Q000188:drug therapy
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D003911:Dextrans; D008937:Mitomycins